Agilent Technologies Inc.
AAgilent Technologies Inc. (A) is a global leader in life sciences, diagnostics, and applied chemical markets. It specializes in designing and manufacturing equipment and software for laboratory analysis, offering solutions for research, pharmaceutical development, and clinical diagnostics. The company originated from Hewlett-Packard's scientific instruments division and has established a strong presence in analytical instrumentation, testing, and measurement services.
Dividend History
Investors can expect a dividend payout of $0.26 per share, scheduled to be distributed in 4 days on July 22, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 22, 2026 | $0.26 | 2026-06-30 | 2026-06-30 |
| April 22, 2026 | $0.26 | 2026-03-31 | 2026-03-31 |
| January 28, 2026 | $0.26 | 2026-01-06 | 2026-01-06 |
| October 22, 2025 | $0.25 | 2025-09-30 | 2025-09-30 |
| July 23, 2025 | $0.25 | 2025-07-01 | 2025-07-01 |
Dividends Summary
- Consistent Payer: Agilent Technologies Inc. has rewarded shareholders with 58 dividend payments over the past 14 years.
- Total Returned Value: Investors who held A shares during this period received a total of $9.86 per share in dividend income.
- Latest Payout: The most recent dividend of $0.26/share was paid 87 days ago, on April 22, 2026.
- Yield & Schedule: A currently pays dividends quarterly with an annual yield of 0.77%.
- Dividend Growth: Since 2012, the dividend payout has grown by 155.0%, from $0.10 to $0.26.
- Dividend Reliability: A has maintained or increased its dividend for 47 consecutive payments.
Company News
The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth a...
The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment...
The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with ...
The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and...
The global Oxidative Stress Assay Market is projected to grow at a CAGR of 9.53% from 2026 to 2035, driven by rising chronic disease prevalence, pharmaceutical R&D investments, and advancements in biomarker diagnostics. North America leads with 38.52% market share, while Asia-Pacific is expected to show the highest growth rate at 10.55%. ELISA te...
